FrancophonIA/ELRC3.0 huggingface dataset:
English: Maviret can only be obtained with a prescription, and treatment should be started and monitored by a doctor experienced in the management of patients with hepatitis C virus infection.
Danish: Maviret udleveres kun efter recept, og behandlingen bør iværksættes og overvåges af en læge med erfaring i behandling af patienter inficeret med hepatitis C-virus.
English: The company that markets Maviret will carry out a study in patients who previously have had liver cancer to evaluate the risk of liver cancer returning after treatment with direct-acting antivirals such as Maviret.
Danish: Virksomheden, der markedsfører Maviret, vil gennemføre et studie med deltagelse af patienter, der tidligere har haft leverkræft, for at vurdere risikoen for, at kræften vender tilbage efter behandling med direkte virkende antivirale lægemidler såsom Maviret.
English: In 8 main studies involving over 2,300 adults with hepatitis C, 99% of non-cirrhotic patients with genotype 1, the most common genotype, tested negative for the virus after 8 weeks of Maviret treatment and 97% cirrhotic patients were negative after 12 weeks.
Danish: I otte hovedstudier med deltagelse af over 2.300 voksne med hepatitis C testede 99 % af patienterne uden skrumpelever med genotype 1, den mest almindelige genotype, negative for virusset efter otte ugers behandling med Maviret, og 97 % af patienterne med skrumpelever negative efter 12 uger.
English: • atorvastatin, simvastatin (medicines for lowering cholesterol levels in the blood);
Danish: • atorvastatin, simvastatin (lægemidler til sænkning af kolesterolindholdet i blodet)
English: The active substances in Maviret, glecaprevir and pibrentasvir, block two proteins essential for the hepatitis C virus to multiply.
Danish: De aktive stoffer i Maviret, glecaprevir og pibrentasvir, blokerer to proteiner, som hepatitis C-virusset behøver for at formere sig.
English: For the full list of restrictions and side effects with Maviret, see the package leaflet.
Danish: Den fuldstændige liste over begrænsninger og bivirkninger ved Maviret fremgår af indlægssedlen.
English: Maviret contains the active substances glecaprevir and pibrentasvir.
Danish: Maviret indeholder de aktive stoffer glecaprevir og pibrentasvir.
English: Maviret is an antiviral medicine used to treat adults and adolescents aged 12 years and older with chronic (long-term) hepatitis C, an infectious disease that affects the liver, which is caused by the hepatitis C virus.
Danish: Maviret er et antiviralt lægemiddel, der anvendes til behandling af voksne og af unge i alderen 12 år og opefter med kronisk hepatitis C, der er en smitsom sygdom, som angriber leveren og forårsages af hepatitis C-virussen.
English: How is Maviret used?
Danish: Hvordan anvendes Maviret?
English: What benefits of Maviret have been shown in studies?
Danish: Hvilke fordele viser studierne, at der er ved Maviret?
English: This study is being carried out in light of data suggesting that patients treated with medicines belonging to the same class as Maviret and who have had liver cancer could be at risk of their cancer returning early.
Danish: der indikerer, at patienter, der har haft leverkræft, og som behandles med lægemidler i samme klasse som Maviret, kan have en risiko for, at kræften vender hurtigt tilbage.
English: • ethinyl estradiol-containing products (such as contraceptive medicines);
Danish: • ethinylestradiol-holdige produkter (som f.eks. svangerskabsforebyggende lægemidler)
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Maviret have also been included in the summary of product characteristics and the package leaflet.
Danish: Der er desuden anført anbefalinger og forholdsregler i produktresuméet og indlægssedlen, som patienter og sundhedspersonale skal følge for at sikre risikofri og effektiv anvendelse af Maviret.
English: How does Maviret work?
Danish: Hvordan virker Maviret?
English: Per 0.1 ml dose * propagated in fertilised hens' eggs from healthy chicken flocks ** haemagglutinin
Danish: per 0,1 ml-dosis opformeret i befrugtede hønseæg fra raske kyllingebesætninger ** haemagglutinin
English: MA (EU) number (Invented) name Strength Pharmaceutical
Danish: MF (EU)-nummer (Særnavn) Navn
English: A/Michigan/45/2015 (H1N1)pdm09 - like strain (A/Michigan/45/2015, NYMC X-275)………………………………...15 micrograms HA** A/Hong Kong/4801/2014 (H3N2) - like strain (A/Hong Kong/4801/2014, NYMC X-263B)........................15 micrograms HA** B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, wild type)…………………………………………………………….….15 micrograms HA**
Danish: A/Hong Kong/4801/2014 (H3N2) - lignende stamme (A/Hong Kong/4801/2014, NYMC X-263B)
English: Influenza virus (inactivated, split) of the following strains*:
Danish: --1 Influenzavirus (inaktiveret, split) fra følgende stammer*: A/Michigan/45/2015 (H1N1)pdm09 - lignende stamme (A/Michigan/45/2015, NYMC X-275)
English: Eighty percent (80 %) of the subjects had a body mass index (BMI)  27.
Danish: 80 % af forsøgspersonerne havde et body mass index (BMI) på  27.
English: • if you are 75 years old or older, you should not start taking Edistride.
Danish: • Hvis du er over 75 år, bør du ikke begynde at tage Edistride.
English: Fifty-one percent (51 %) of the subjects were men, 84 % were White, 9 % were Asian, 3 % were Black and 4 % were of other racial groups.
Danish: 51 % af forsøgspersonerne var mænd, 84 % var hvide, 9 % var asiatiske, 3 % var sorte og 4 % kom fra andre racegrupper.
English: C]-dapagliflozin dose, 96 % was recovered, 75 % in urine and 21 % in feces.
Danish: C]-dapagliflozindosis blev 96 % genfundet, 75 % i urinen og 21 % i afføringen.
English: • if you are taking another medicine for diabetes that contains “pioglitazone”, you should not start taking Edistride.
Danish: • Hvis du tager et andet lægemiddel mod diabetes, der indeholder pioglitazon, bør du ikke begynde at tage Edistride.
English: • Edistride is used if your diabetes cannot be controlled with other medicines for diabetes, diet and exercise.
Danish: • Edistride anvendes, hvis din diabetes ikke kan kontrolleres med andre antidiabetiske lægemidler, diæt og motion.
English: All RMPs should be updated accordingly via an appropriate variation to be submitted no later than one month of the European Commission decision;
Danish: Alle risikostyringsplaner bør opdateres i overensstemmelse hermed gennem en variationsansøgning, der skal indsendes senest én måned efter EuropaKommissionens afgørelse.
English: In particular, if you are following a diabetic weight control diet, continue to follow it while you are taking Edistride.
Danish: Især hvis du følger en diabetesdiæt med vægtkontrol, skal du fortsat følge denne, mens du tager Edistride.
English: In the clinical program, 34.4 % of subjects had a history of cardiovascular disease (excluding hypertension) at baseline and 67.9 % had hypertension.
Danish: I det kliniske udviklingsprogram havde 34,4 % af forsøgspersonerne en anamnese med kardiovaskulær sygdom (eksklusive hypertension) ved baseline, og 67,9 % havde hypertension.
English: Warnings and precautions Talk to your doctor, pharmacist or nurse before taking Edistride, and during treatment:
Danish: Advarsler og forsigtighedsregler Tal med din læge, apotekspersonalet eller sundhedspersonalet, før du begynder at tage Edistride og under behandlingen:
English: • Do not use this medicine after the expiry date, which is stated on the blister or carton after ‘EXP'.
Danish: • Brug ikke Edistride efter den udløbsdato ("EXP"), der står på blisterkort og pakning.
English: Adverse reactions in placebo-controlled studies System organ class
Danish: Bivirkninger i placebokontrollerede studier Systemorgan
English: Your doctor may want to lower the dose of these other medicines, to prevent you from getting low blood sugar levels (hypo-glycaemia).
Danish: Din læge kan ønske at nedsætte dosen af disse andre lægemidler for at undgå at du får for lavt blodsukker (hypoglykæmi).
English: Edistride is used for a type of diabetes called “type 2 diabetes mellitus” in adult patients (aged 18 years and older).
Danish: Edistride anvendes til en type diabetes kaldet "type 2-diabetes mellitus" hos voksne patienter (over 18 år).
English: • Your doctor may ask you to take Edistride on its own if you are intolerant to metformin or together with other medicines to treat diabetes.
Danish: • Lægen kan bede dig om at tage Edistride alene, hvis du ikke kan tåle metformin, eller sammen med anden medicin til behandling af diabetes.
English: Edistride is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as:
Danish: Edistride er indiceret til voksne personer på 18 år eller ældre med type 2-diabetes mellitus for at forbedre den glykæmiske kontrol, som:
English: Further evaluation of patients who had renal-related adverse events showed that most had serum creatinine changes of ≤ 0.5 mg/dl from baseline.
Danish: Yderligere undersøgelse af patienter, som havde bivirkninger relateret til nyrerne, viste, at de fleste havde en ændring i serumkreatinin på ≤ 0,5 mg/dl fra baseline.
English: Cardiovascular death, MI and stroke were observed with a hazard ratio of 0.77 (95 % CI: 0.54, 1.10).
Danish: For kardiovaskulær død, MI og stroke observeredes en hazard ratio på 0,77 (95 % CI: 0,54, 1,10).
English: Edistride should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Danish: Edistride må ikke anvendes til patienter med type 1-diabetes mellitus eller til behandling af diabetisk ketoacidose.
English: This glucose excretion (glucuretic effect) is observed after the first dose, is continuous over the 24-hour dosing interval and is sustained for the duration of treatment.
Danish: Denne udskillelse af glucose (glukuretisk effekt) observeres efter den første dosis, fortsætter over doseringsintervallet på 24 timer og varer ved i hele behandlingsperioden.
English: Final analysis of these studies, after unblinding, will provide further information on the benefit/risk of SGLT2 inhibitors particularly of the risk of lower limb amputations.
Danish: Den endelige analyse af disse undersøgelser vil efter afblinding give yderligere oplysninger om benefit/risk-forholdet for SGLT2-hæmmere, især hvad angår risikoen for amputation af nedre ekstremiteter.
English: on one side and “1427” on the other side.
Danish: "5" på den ene side og "1427" på den anden side.
English: Fifty-two percent (52 %) had mild renal impairment and 11 % had moderate renal impairment.
Danish: 52 % havde let nedsat nyrefunktion, og 11 % havde moderat nedsat nyrefunktion.
English: More information is given below in Other medicines and Edistride.
Danish: Der gives yderligere oplysninger under Brug af anden medicin sammen med Edistride.
English: Administration with a high-fat meal decreased dapagliflozin Cmax by up to 50 % and prolonged Tmax by approximately 1 hour, but did not alter AUC as compared with the fasted state.
Danish: Indgivelse med et fedtrigt måltid reducerede dapagliflozin Cmax med op til 50 % og forlængede Tmax med ca. 1 time, men ændrede ikke AUC i sammenligning med den fastende tilstand.
English: Combination of a single dose of dapagliflozin 20 mg and simvastatin (a CYP3A4 substrate) resulted in a 19 % increase in AUC of simvastatin and 31 % increase in AUC of simvastatin acid.
Danish: En kombination af en enkeltdosis dapagliflozin 20 mg og simvastatin (et CYP3A4-substrat) resulterede i en 19 % stigning i AUC for simvastatin og en 31 % stigning i AUC for simvastatinsyre.
English: a) in a placebo-controlled study of dapagliflozin in combination with insulin (alone or with oral glucose-lowering medicinal products)
Danish: a) i et placebokontrolleret studie af dapagliflozin i kombination med insulin (alene eller med orale glucosesænkende lægemidler)
English: In a pre-specified pooled analysis of 13 placebo-controlled studies, 2,360 subjects were treated with dapagliflozin 10 mg and 2,295 were treated with placebo.
Danish: I en planlagt puljet analyse af 13 placebo-kontrollerede studier blev 2.360 forsøgspersoner behandlet med dapagliflozin 10 mg, og 2.295 blev behandlet med placebo.
English: glimepiride 4 mg/day; Metformin (immediate- or extended-release formulations) ≥1500 mg/day plus maximum tolerated dose, which must be at least half maximum dose, of a sulphonylurea for at least 8 weeks prior to enrolment.
Danish: 2Metformin (formulering med umiddelbar (IR) eller forlænget frigivelse (XR)) ≥1500 mg/dag plus maksimal tolereret dosis, som skal være mindst halvdelen af den maksimale dosis, af et sulfonylurinstof i mindst 8 uger inden inkludering i studiet.
English: Urine laboratory assessments Due to its mechanism of action, patients taking Edistride will test positive for glucose in their urine.
Danish: På grund af lægemidlets virkningsmekanisme vil patienter, der tager Edistride, få et positivt analyseresultat for glucose i urinen.
English: During clinical trials, the overall proportion of subjects with malignant or unspecified tumours was similar between those treated with dapagliflozin (1.50 %) and placebo/comparator (1.50 %), and there was no carcinogenicity or mutagenicity signal in animal data (see section 5.3).
Danish: I kliniske studier var den samlede andel af forsøgspersoner med maligne eller uspecificerede tumorer den samme blandt dem, der blev behandlet med dapagliflozin (1,50 %) og placebo/comparator (1,50 %), og der sås ingen tegn på karcinogenicitet eller mutagenicitet i dyredata (se pkt.
English: Mean percent change from baseline for dapagliflozin 10 mg versus placebo, respectively, was: total cholesterol 2.5 % versus 0.0 %; HDL cholesterol 6.0 % versus 2.7 %; LDL cholesterol 2.9 % versus -1.0 %; triglycerides -2.7 % versus -0.7 %.
Danish: Den gennemsnitlige procentvise ændring fra baseline for dapagliflozin 10 mg versus placebo var hhv.: Total kolesterol 2,5 % versus 0,0 %; HDL-kolesterol 6,0 % versus 2,7 %; LDL-kolesterol 2,9 % versus -1,0 %; triglycerider -2,7 % versus -0,7 %.
English: Diabetic Ketoacidosis
Danish: Diabetisk ketoacidose
English: Sulphonylurea (glimepiride
Danish: Sulfonylurinstof (glimepirid
English: Placebo + insulin ± oral glucose-lowering medicinal products
Danish: Placebo + insulin ± orale glucosesænkende lægemidler
English: Geometric mean steady-state dapagliflozin Cmax and AUCτ values following once daily 10 mg doses of dapagliflozin were 158 ng/ml and 628 ng h/ml, respectively.
Danish: De geometriske gennemsnitlige steady state Cmax- og AUCτ-værdier for dapagliflozin efter én daglig 10 mg dosis dapagliflozin var henholdsvis 158 ng/ml og 628 ng t/ml.
English: a) of a placebo-controlled study of dapagliflozin as monotherapy
Danish: a) af et placebo-kontrolleret studie af dapagliflozin som monoterapi
English: Primary episodes occurred at a rate of 1.62 % per patient-year in subjects treated with dapagliflozin and 2.06 % in comparator-treatment subjects, per patient-year.
Danish: De primære episoder indtraf med en procentdel på 1,62 % pr. patientår hos forsøgspersoner behandlet med dapagliflozin, og med 2,06 % hos forsøgspersoner behandlet med comparator pr. patientår.
English: • Edistride 10 mg film-coated tablets are yellow and diamond-shaped approximately 1.1 x 0.8 cm diagonally.
Danish: • Edistride 10 mg filmovertrukne tabletter er gule og diamantformede og måler ca. 1,1 x 0,8 cm diagonalt.
English: • Edistride 5 mg film-coated tablets are yellow and round with diameter of 0.7 cm.
Danish: • Edistride 5 mg filmovertrukne tabletter er gule og runde med en diameter på 0,7 cm. Der står
English: DPP-4 Inhibitor (sitagliptin 2) ± Metformin
Danish: DPP-4-hæmmer (sitagliptin ± metformin
English: Small increases in serum PTH levels were observed with increases being larger in subjects with higher baseline PTH concentrations.
Danish: Der er observeret mindre stigninger i serumkoncentrationen af PTHog stigningerne var større hos forsøgspersoner med højere serum-PTH ved baseline.
English: For studies of dapagliflozin in monotherapy, as add-on to metformin or as add-on to sitagliptin (with or without metformin), the frequency of minor episodes of hypoglycaemia was similar (< 5 %) between treatment groups, including placebo up to 102 weeks of treatment.
Danish: Ved studier af dapagliflozin i monoterapi, som tillægsbehandling til metformin eller som tillægsbehandling til sitagliptin (med eller uden metformin), var hyppigheden af mindre alvorlige tilfælde af hypoglykæmi omtrent den samme (< 5 %) i alle behandlingsgrupper, inklusive placebo, ved op til 102 ugers behandling.
English: a) placebo-controlled studies of dapagliflozin in add-on combination with metformin or sitagliptin (with or without metformin) Add-on combination
Danish: a) placebokontrollerede studier af dapagliflozin i tillægskombination med metformin eller sitagliptin (med eller uden metformin) Tillægskombination
English: 104 and 208 weeks, a significantly lower proportion of subjects in the group treated with dapagliflozin (3.5 %, 4.3 % and 5.0 %, respectively) experienced at least one event of hypoglycaemia compared to the group treated with glipizide (40.8 %, 47.0 % and 50.0 %, respectively).
Danish: Ved uge 52, 104 og 208 havde en betydeligt lavere andel af forsøgspersonerne i dapagliflozin-gruppen (hhv. 3,5 %, 4,3 % og 5,0 %) oplevet mindst ét tilfælde af hypoglykæmi sammenlignet med med glipizid-gruppen (hhv. 40,8 %, 47,0 % og 50,0 %).
English: Moderate renal impairment (eGFR ≥ 30 to < 60 ml/min/1.73 m The efficacy of dapagliflozin was also assessed separately in a dedicated study of diabetic subjects with moderate renal impairment (252 subjects with mean eGFR 45 ml/min/1.73 m2).
Danish: Moderat nedsat nyrefunktion (eGFR ≥ 30 til < 60 ml/min/1,73 m Effekten af dapagliflozin blev også vurderet separat i et studie med forsøgspersoner med diabetes med moderat nedsat nyrefunktion (252 forsøgspersoner med en gennemsnitlig eGFR på 45 ml/min/1,73 m2).
English: At steady-state (20 mg once-daily dapagliflozin for 7 days), subjects with type 2 diabetes mellitus and mild, moderate or severe renal impairment (as determined by iohexol plasma clearance) had mean systemic exposures of dapagliflozin of 32 %, 60 % and 87 % higher, respectively, than those of subjects with type 2 diabetes mellitus and normal renal function.
Danish: Ved steady state (20 mg dapagliflozin én gang dagligt i 7 dage) havde forsøgspersoner med type 2diabetes mellitus og let, moderat eller svært nedsat nyrefunktion (i henhold til iohexol plasmaclearance) gennemsnitlige systemiske eksponeringer for dapagliflozin, der var henholdsvis 32 %, 60 % og 87 % højere end dem hos forsøgspersoner med type 2-diabetes mellitus og normal nyrefunktion.
English: Urinary tract infections were more frequently reported for dapagliflozin 10 mg compared to placebo (4.7 % versus 3.5 %, respectively; see section 4.4).
Danish: Urinvejsinfektioner blev hyppigere rapporteret for dapagliflozin 10 mg sammenlignet med placebo (4,7 % versus 3,5 %, se pkt.
English: These reactions were more common in patients with baseline eGFR ≥ 30 and < 60 ml/min/1.73 m2 (18.5 % dapagliflozin 10 mg vs 9.3 %
Danish: Disse reaktioner var mere almindelige hos patienter med baseline eGRF ≥ 30 og < 60 ml/min/1,73m2 (18,5 % dapagliflozin 10 mg versus 9,3 % placebo).
English: The following adverse reactions have been identified in the placebo-controlled clinical trials.
Danish: Oversigt over bivirkninger i tabelform Følgende bivirkninger er identificeret i de placebokontrollerede kliniske studier.
English: Minor episodes of hypoglycaemia were reported in 12.8 % of subjects who received dapagliflozin 10 mg plus metformin and a sulphonylurea and in 3.7 % of subjects who received placebo plus metformin and a sulphonylurea.
Danish: Der blev rapporteret lettere tilfælde af hypoglykæmi hos 12,8 % af de forsøgspersoner, som fik dapagliflozin 10 mg plus metformin og et sulfonylurinstof, og hos 3,7 % af de forsøgspersoner, som fik placebo plus metformin og et sulfonylurinstof.
English: In subjects with mild or moderate hepatic impairment (Child-Pugh classes A and B), mean Cmax and AUC of dapagliflozin were up to 12 % and 36 % higher, respectively, compared to healthy matched control subjects.
Danish: Hos forsøgspersoner med let eller moderat nedsat leverfunktion (Child-Pugh klasse A og B), var det gennemsnitlige Cmax og AUC af dapagliflozin op til henholdsvis 12 % og 36 % højere sammenlignet med tilsvarende raske kontrolpersoner.
English: Edistride 5 mg tablets and Edistride 10 mg tablets are available in aluminium blisters in pack sizes of 14, 28 or 98 film-coated tablets in non-perforated calendar blisters and 30x1 or 90x1 film-coated tablets in perforated unit dose blisters.
Danish: Edistride 5 mg tabletter og Edistride 10 mg tabletter fås som blisterkort af aluminium i pakninger med 14, 28 eller 98 filmovertrukne tabletter i ikke-perforerede kalender-blisterkort og 30x1 eller 90x1 filmovertrukne tabletter i perforerede enkeltdosis-blisterkort.
English: Columns 1 and 2, HbA1c analysed using LOCF (see footnote d); Columns 3 and 4, HbA1c analysed using LRM (see footnote e) Least squares mean adjusted for baseline value LOCF: Last observation (prior to rescue for rescued subjects) carried forward LRM: Longitudinal repeated measures analysis p-value < 0.0001 versus placebo + oral glucose-lowering medicinal product(s)
Danish: Kolonne 1 og 2, HbA1c analyseret under anvendelse af LOCF (se fodnote d); Kolonne 3 og 4, HbA1c analyseret under anvendelse af LRM (se fodnote e) Gennemsnit beregnet efter mindste kvadraters metode justeret for baselineværdi LOCF: Last observation carried forward (før behandling med rescue-medicin) LRM: Longitudinal analyse af gentagne målinger p-værdi < 0,0001 versus placebo + oralt glucosesænkende lægemiddel/lægemidler
English: Haematocrit values >55 % were reported in 1.3 % of the subjects treated with dapagliflozin 10 mg versus 0.4 % of placebo subjects.
Danish: Hæmatokrit værdier > 55 % blev rapporteret hos 1,3 % af forsøgspersonerne behandlet med 10 mg dapagliflozin versus 0,4 % for placebo.
English: tablet core: microcrystalline cellulose (E460i), anhydrous lactose (see section 2 ‘Edistride contains lactose'), crospovidone (E1202), silicon dioxide (E551), magnesium stearate (E470b).
Danish: • Øvrige indholdsstoffer: tabletkerne: mikrokrystallinsk cellulose (E460i), vandfri laktose (se punkt 2 "Edistride indeholder laktose"), crospovidon (E1202), siliciumdioxid (E551), magnesiumstearat (E470b).
English: In an add-on to glimepiride study, at weeks 24 and 48, minor episodes of hypoglycaemia were reported more frequently in the group treated with dapagliflozin 10 mg plus glimepiride (6.0 % and 7.9 %, respectively) than in the placebo plus glimepiride group (2.1 % and 2.1 %, respectively).
Danish: I et studie med tillægsbehandling til glimepirid blev der i uge 24 og 48 hyppigere rapporteret mindre alvorlige tilfælde af hypoglykæmi i gruppen behandlet med dapagliflozin 10 mg plus glimepirid (6,0 % hhv. 7,9 %) end i gruppen, der fik placebo plus glimepirid (2,1 % hhv. 2,1 %).
English: UAB AstraZeneca Lietuva Tel: +370 5 2660550
Danish: UAB AstraZenecaLietuva Tel: +370 5 2660550
English: In a 52-week, active-controlled non-inferiority study (with 52- and 104-week extension periods), Edistride was evaluated as add-on therapy to metformin compared with a sulphonylurea (glipizide) as add-on therapy to metformin in subjects with inadequate glycaemic control (HbA1c > 6.5 % and ≤ 10 %).
Danish: Edistride blev evalueret i et 52-ugers aktivt kontrolleret non-inferioritets studie (med forlængelsesperioder på 52 og 104 uger) som tillægsbehandling til metformin sammenlignet med et sulfonylurinstof (glipizid) som tillægsbehandling til metformin hos forsøgspersoner med utilstrækkelig glykæmisk kontrol (HbA1c > 6,5 % og ≤ 10 %).
English: Haematocrit increased Creatinine renal clearance decreased Dyslipidaemia
Danish: Forhøjet hæmatokrit Nedsat renal kreatininclearance Dyslipidæmi
English: Urine glucose Because of how Edistride works, your urine will test positive for sugar while you are on this medicine.
Danish: På grund af Edistrides virkemåde vil urinprøver vise, at du har sukker (glucose) i urinen, mens du tager denne medicin.